MedPath

Beating Heart Mitral Valve REPair With the HARPOON™ System: ReaL World Outcomes From a multICenter observATional European Registry

Conditions
Severe Degenerative Mitral Regurgitation Due to Mid-segment Posterior Leaflet Prolapse
Registration Number
DRKS00022785
Lead Sponsor
Harpoon Medical, an indirect wholly-owned subsidiary of Edwards Lifesciences Corporation, Edwards Lifesciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting stopped after recruiting started
Sex
All
Target Recruitment
26
Inclusion Criteria

Subjects who are clinically suitable for treatment with the HARPOON™ System, as per the Instructions for Use (IFU), will be evaluated for inclusion in the registry.

Exclusion Criteria

N/A

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Freedom from re-operation due to recurrent severe mitral regurgitation through 1-year post-implant<br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath